Compare Pfizer Inc (PFE) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Zscaler Inc — how do they compare? Pfizer Inc trades at $28.28 (market cap $158.56B), while Zscaler Inc trades at $233.73 (market cap $35.35B). The key difference: Pfizer Inc is far larger — about 4.5× Zscaler Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Zscaler Inc for 41 Days on average.
| PFE | ZS | |
|---|---|---|
Market Cap | $158.56B | $35.35B |
Volume | 44,138,282 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $29.02 | $336.27 |
52-Week Low | $23.67 | $118.05 |
Typical Hold Time | 158 Days | 41 Days |
Enterprise Value | $210.06B | $33.73B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Zscaler (ZS) trades at $216.99, up 1.61% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -1.88% net margin. Recent quarters have consistently beaten EPS estimates, while analyst sentiment remains overwhelmingly positive with 79.63% buy ratings and a $222.83 consensus target.
ZS presents growth potential through cybersecurity demand and AI product expansion, but faces execution risks from leadership changes and competitive pressures. The stock trades at premium valuations (P/S 10.36) while still losing money, creating both opportunity and vulnerability if growth slows or margins don't improve as expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
